Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

JD101 Oct. 4 at 1:05 AM

$GNLX $10-$15 on data

0 · Reply

Kupper Oct. 3 at 6:55 PM

$GNLX those of you selling for pennies will regret it.

0 · Reply

thesaltier1 Oct. 3 at 1:29 PM

$GNLX we have been consolidating in this range for awhile, I expect a breakout above $5 before the end of the month

0 · Reply

Kupper Sep. 25 at 12:09 AM

$GNLX Should do away with pre and post market trading. Allows for too much manipulation on small volumes.

1 · Reply

Stark50 Sep. 24 at 8:19 PM

$GNLX a mighty 475 watches :)

1 · Reply

JD101 Sep. 23 at 3:07 PM

$GNLX breaking out

0 · Reply

JessePhelps536 Sep. 21 at 5:05 PM

$GNLX Biopharmaceutical speculation. Pre-revenue volatility. High risk/reward setup. No pattern.

1 · Reply

FrodoBag Sep. 18 at 7:48 PM

$GNLX any chance that phase 3 data got pushed to next year because survival lengths (pfs) are longer than expected?

1 · Reply

JD101 Sep. 18 at 3:38 PM

$GNLX data will be here within the next 4 weeks imo

0 · Reply

JD101 Sep. 18 at 12:21 PM

$LIXT $GNLX $VVOS $PBM my 4 bio horseman .. each one still can 10X from current levels

2 · Reply

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Jul 7, 2025, 7:00 AM EDT - 3 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

May 6, 2025, 4:10 PM EDT - 5 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Mar 28, 2025, 4:10 PM EDT - 6 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 8:31 AM EDT - 6 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 8 months ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 10 months ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 11 months ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 31, 2024, 10:59 AM EDT - 1 year ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 1 year ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 2 years ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 2 years ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 26, 2023, 10:50 PM EDT - 2 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 2 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 2 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

JD101 Oct. 4 at 1:05 AM

$GNLX $10-$15 on data

0 · Reply

Kupper Oct. 3 at 6:55 PM

$GNLX those of you selling for pennies will regret it.

0 · Reply

thesaltier1 Oct. 3 at 1:29 PM

$GNLX we have been consolidating in this range for awhile, I expect a breakout above $5 before the end of the month

0 · Reply

Kupper Sep. 25 at 12:09 AM

$GNLX Should do away with pre and post market trading. Allows for too much manipulation on small volumes.

1 · Reply

Stark50 Sep. 24 at 8:19 PM

$GNLX a mighty 475 watches :)

1 · Reply

JD101 Sep. 23 at 3:07 PM

$GNLX breaking out

0 · Reply

JessePhelps536 Sep. 21 at 5:05 PM

$GNLX Biopharmaceutical speculation. Pre-revenue volatility. High risk/reward setup. No pattern.

1 · Reply

FrodoBag Sep. 18 at 7:48 PM

$GNLX any chance that phase 3 data got pushed to next year because survival lengths (pfs) are longer than expected?

1 · Reply

JD101 Sep. 18 at 3:38 PM

$GNLX data will be here within the next 4 weeks imo

0 · Reply

JD101 Sep. 18 at 12:21 PM

$LIXT $GNLX $VVOS $PBM my 4 bio horseman .. each one still can 10X from current levels

2 · Reply

Kupper Sep. 17 at 8:18 PM

$GNLX these downturns are buying opportunities.

0 · Reply

JD101 Sep. 16 at 6:28 PM

$GNLX $10 first then 🌙

1 · Reply

FrodoBag Sep. 16 at 6:26 PM

$GNLX the days of buying this on sale may be over…

0 · Reply

Orlandotrader Sep. 16 at 6:03 PM

$GNLX Come on now….. Let’s Break out.

0 · Reply

Kupper Sep. 15 at 6:03 PM

$GNLX nobody should be selling or shorting this.

0 · Reply

SoaringEagles Sep. 13 at 10:02 PM

Make sure you guys have ticker MITQ on watch. This is getting lot of buzz, rightfully so. Small float is the theme right now and market is picking up on MITQ. Imagine how far can this can go if all retail came together to send this, easily double digit. Be early on MITQ and don't miss out the explosion. Watching $APLD $GNLX $ARTL $BREA

0 · Reply

JD101 Sep. 12 at 9:51 PM

$LIXT $GNLX $VVOS $PBM

0 · Reply

Biotechnicity Sep. 12 at 4:25 PM

$GNLX added yesterday. Feels good today.

0 · Reply

Orlandotrader Sep. 12 at 3:46 PM

$GNLX Nice Moves!!!

0 · Reply

JD101 Sep. 12 at 2:58 PM

$GNLX $40+ on good data

2 · Reply

Stark50 Sep. 12 at 2:49 PM

$GNLX nice moves this week

0 · Reply

JD101 Sep. 9 at 2:14 PM

$LIXT $GNLX $VVOS $PBM $TNYA all in on these 5 bios … each one massive potential

1 · Reply

Market Cap	168.09M
Revenue (ttm)	10,000.00
Net Income (ttm)	-29.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-298,700.02%
Debt to Equity Ratio	0.00

Volume	99,300
Avg Vol	121,828
Day's Range	N/A - N/A
Shares Out	37.77M
Stochastic %K	69%
Beta	-0.22
Analysts	Strong Sell
Price Target	$17.60